Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 8/20 | 0.37 |
| ▸ | ACVRL1 | P37023 | 10/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.35 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.35 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.35 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23834529 | 0.82 | ACVRL1 (0.43) | PIK3CDACVRL1MTORRICTORRPTOR | |
| SCHEMBL31391141 | 0.79 | ACVRL1 (0.49) | PIK3CDACVRL1MTORRICTORRPTOR | |
| SCHEMBL19429526 | 0.75 | ACVRL1 (0.45) | PIK3CDACVRL1MTORRICTORRPTOR | |
| SCHEMBL19377710 | 0.74 | ACVRL1 (0.44) | PIK3CDACVRL1MTORRICTORRPTOR | |
| SCHEMBL25172261 | 0.73 | PIK3CD (0.44) | PIK3CDACVRL1MTORRICTORRPTOR | |
| SCHEMBL16011301 | 0.73 | ACVRL1 (0.58) | PIK3CDACVRL1MTORRICTORRPTOR | |
| SCHEMBL19377690 | 0.73 | ACVRL1 (0.61) | PIK3CDACVRL1MTORRICTORRPTOR | |
| SCHEMBL19377805 | 0.73 | PIK3CD (0.53) | PIK3CDACVRL1CSNK2A2CSNK2A1 | |
| SCHEMBL16011302 | 0.73 | ACVRL1 (0.58) | PIK3CDACVRL1MTORRICTORRPTOR | |
| SCHEMBL25171216 | 0.73 | ACVRL1 (0.44) | PIK3CDACVRL1CSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11963960-B2 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | FLASH THERAPEUTICS, LLC (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4121430-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | Flash Therapeuttics, LLC (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11963960-B2 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | MCL1, FLT3, ABL1 | PIK3CD 3008/4885ACVRL1 3748/4885MTOR 855/4885 |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | MCL1, FLT3, ABL1 | PIK3CD 3008/4885ACVRL1 3748/4885MTOR 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.